Oragenics (NYSE:OGEN) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report released on Thursday. The firm set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of Oragenics stock opened at $0.32 on Thursday. The firm has a fifty day moving average of $0.34 and a two-hundred day moving average of $0.96. The stock has a market capitalization of $3.88 million, a price-to-earnings ratio of -0.04 and a beta of 0.49. Oragenics has a 52 week low of $0.25 and a 52 week high of $7.74.

Institutional Trading of Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new stake in Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent SEC filing. 18.71% of the stock is currently owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.